Prospects for new restorative and neuroprotective treatments in Parkinson's disease

@article{Dunnett1999ProspectsFN,
  title={Prospects for new restorative and neuroprotective treatments in Parkinson's disease},
  author={Stephen B. Dunnett and Anders Bj{\"o}rklund},
  journal={Nature},
  year={1999},
  volume={399},
  pages={A32-A39}
}
The degeneration of forebrain dopamine systems in Parkinson's disease has been an effective target for pharmaceutical research over the past four decades. However, although dopamine replacement may alleviate the symptoms of the disease, it does not halt the underlying neuronal degeneration. The past decade has seen major advances in identifying discrete genetic and molecular causes of parkinsonism and mapping the events involved in nigral cell death. This new understanding of the pathogenesis… Expand
Parkinson's disease: molecular aspects and prospective neuroprotective and restorative therapies
TLDR
This review summarizes most recent insights gained from many studies in Parkinson's disease and identifies the cascade of deleterious events that lead to the dysfunction and death of dopaminergic neurons. Expand
Parkinson's disease: molecular aspects and prospective neuroprotective and restorative therapies
TLDR
This review summarizes most recent insights gained from many studies in PD and identifies the cascade of deleterious events that lead to the dysfunction and death of dopaminergic neurons. Expand
Neuroprotective and neurorestorative strategies for Parkinson's disease
Advances in understanding the molecular mechanisms of cell death and the pathogenesis of sporadic and familial Parkinson's disease are creating new opportunities for the development ofExpand
Antiparkinsonian drugs and their neuroprotective effects.
TLDR
Current findings regarding the pathogenesis and antiparkinsonian drugs are summarized, and their possibilities of targets to develop novel neuroprotective drugs are discussed. Expand
GDNF therapy for Parkinson’s disease
TLDR
This review will examine the experimental and clinical evidence of GDNF use in PD with particular focus on its potential as an effective therapy in the treatment of PD. Expand
Neural transplantation therapies for Parkinson's and Huntington's diseases.
TLDR
The extent to which neural transplantation has successfully been translated into clinical studies for Parkinson's and Huntington's diseases is discussed and the merits of this approach are considered. Expand
Neuroprotection for Parkinson’s disease: a new approach for a new millennium
TLDR
The option of drug-mediated stimulation of endogenous mechanisms responsible for the detoxification of dopamine auto-oxidation products as a novel means of neuroprotection in Parkinson’s disease is discussed. Expand
Restorative Therapies for Parkinson's Disease: Ethical Issues
TLDR
The prospect of brain restorative therapies, such as cell or gene therapy, has raised enormous interest and is seen as a new method to tackle the disease more efficaciously and the ethical issues involved, both from the methodological angle as well as from the patient’s point of view, involved in the development of such treatments are subject of the present chapter. Expand
Disease model: Parkinson's disease.
TLDR
In this review, the available in vivo and in vitro models of PD are summarized and discussed and their value is discussed. Expand
Neurotransplantation and the Restoration of Motor Behavior in Parkinson’s Disease
TLDR
There is a strong need for further development of cell replacement strategies that have the potential not only to restore the lost neuronal pathways but also to provide long-lasting beneficial effects for patients with neurodegenerative diseases. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 125 REFERENCES
Neuroprotection in Parkinson's Disease
TLDR
It is likely that sporadic PD is related to a complex interaction between a variety of genetic and environmental factors that may be different in different individuals and makes it unlikely that a single neuroprotective treatment aimed at interfering with a single etiologic factor will be effective in the majority of PD patients. Expand
Studies on Neuroprotective and Regenerative Effects of GDNF in a Partial Lesion Model of Parkinson's Disease
TLDR
Administration of glial cell line-derived neurotrophic factor (GDNF) appears to be a particularly effective site for induction of axonal sprouting and regeneration accompanied by recovery of spontaneous sensorimotor behaviors in the chronically lesioned nigrostriatal dopamine system. Expand
Oxidative stress and antioxidant therapy in Parkinson's disease
TLDR
Experimental therapeutic refinements to attenuate the effects of oxidative stress and to provide neuroprotection of striatal dopaminergic neurons in Parkinson's disease include blocking dopamine transporter by mazindol, blocking NMDA receptors by dizocilpine maleate, enhancing the survival of neurons by giving brain-derived neurotrophic factors, providing antioxidants such as vitamin E, or inhibiting monoamine oxidase B by selegiline. Expand
Neural transplantation: a hope for patients with Parkinson's disease
TLDR
Clinical trials demonstrate that grafted dopamine neurons can survive in the human parkinsonian brain and reinnervate part of the host striatum and long-term graft survival and function is possible in PD despite a progressive degeneration of the patient's own DA neurons. Expand
Understanding cell death in parkinson's disease
TLDR
Evidence enables us to hypothesize that a failure to process structurally modified proteins in regions of the brain exhibiting oxidative stress is a cause of both familial and sporadic PD. Expand
Application ofex VivoGene Therapy in the Treatment of Parkinson's Disease
TLDR
The utility of CNS-derived neural progenitors as alternative cell types for ex vivo gene therapy in an animal model of Parkinson's disease is explored and the issues and approaches outlined are applicable to other neurodegenerative disorders. Expand
The causes of parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality
TLDR
It is suggested that it may be more profitable to test a large number of agents in a small number of selected patients in search of a more robust neuroprotective effect, to reduce the risk of missing a powerful neuroProtective treatment with a treatment that might not otherwise have been studied because of a lack of time, money, or patients. Expand
Rate of cell death in parkinsonism indicates active neuropathological process
TLDR
Evidence against the hypothesis that idiopathic parkinsonism might be due to age‐related attrition of dopamine neurons occurring long after an initial acute episode is presented, based on the finding of at least six times as many HLA‐DR—positive microglia phagocytosing dopamine neurons in parkinsonian brains as in control brains. Expand
Potential of gene therapy for Parkinson's disease: neurobiologic issues and new developments in gene transfer methodologies.
  • U. Kang
  • Biology, Medicine
  • Movement disorders : official journal of the Movement Disorder Society
  • 1998
TLDR
Current technology of gene therapy is limited in its long-term expression and ability to regulate the gene expression, however, recent developments provide better understanding of these limitations and suggest potential solutions to these technical hurdles. Expand
Dopaminergic Neurons Protected from Degeneration by GDNF Gene Therapy
TLDR
Results suggest that Ad vector-mediated GDNF gene therapy may slow the DA neuronal cell loss in humans with Parkinson's disease. Expand
...
1
2
3
4
5
...